Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27 2022 - 10:00AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing first-in-class allogeneic gamma
delta chimeric antigen receptor (CAR) T cell therapies for cancer,
today announced that updated safety and efficacy data from the
Phase 1 study of ADI-001 for the potential treatment of relapsed or
refractory B-cell Non-Hodgkin’s Lymphoma (NHL) will be delivered as
an oral presentation at the upcoming 2022 American Society of
Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and
online June 3-7, 2022.
Details of the oral presentation are as follows: Abstract
Number: 7509 Abstract Title: A phase 1 study of ADI-001:
Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) t cells in
adults with B-cell malignancies Presenting Author: Sattva
Neelapu, MD, MD Anderson Cancer Center Session Type/Title:
Clinical Science Symposium/ Beating Bad Blood: The Power of
Immunotherapy in Hematologic Malignancies Date: June 6, 2022
Time: 8:00 AM-9:30 AM CDT
The abstract will be available on Thursday, May 26 at 5:00 PM
EDT on ASCO.org.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with CAR and T cell receptor-like
targeting moieties to enhance selective tumor targeting, facilitate
innate and adaptive anti-tumor immune response, and improve
persistence for durable activity in patients. For more information,
please visit our website at http://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220427005290/en/
Adicet Bio., Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2023 to Jul 2024